Brief: Medincell: Additional $4 Mln Received For 6-Month Active Injectable Bioresorbable Subcutaneous Contraceptive

Medincell SA

30/11/2022 17:15

Nov 30 (Reuters) - Medincell SA  MEDCL.PA :
    * ADDITIONAL US$ 4 MILLION RECEIVED FOR NEXT DEVELOPMENT
STEPS OF
MEDINCELL'S 6-MONTH ACTIVE INJECTABLE BIORESORBABLE SUBCUTANEOUS
CONTRACEPTIVE
    * MEDINCELL (PARIS:MEDCL) HAS RECEIVED AN ADDITIONAL US$ 4
MILLION
PAYMENT FROM BILL & MELINDA GATES FOUNDATION
    * THIS AMOUNT IS INTENDED TO FINANCE NEXT STEPS OF
MEDINCELL'S
PROGRAM MDC-WWM IN READINESS TO INITIATE FIRST CLINICAL TRIAL
END OF 2023

Source text for Eikon:  ID:nBwqtcPZa 
Further company coverage:  MEDCL.PA 
 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))